The Cocktail Report (sounds really smart around your friends):
Mayo Clinic researchers published a study in eBioMedicine (a Lancet journal) showing that a combination of dasatinib (a leukemia drug) and quercetin (a plant-derived supplement) cleared senescent cells from diabetic kidneys and restored organ function in preclinical models.
Senescent cells, often called "zombie cells," are damaged cells that refuse to die. Instead of clearing out, they linger and release a steady stream of inflammatory signals that accelerate aging and damage surrounding tissue.
The treatment is described as "hit-and-run": just five days of oral dosing reduced kidney injury, decreased fibrosis (scarring), and lowered inflammation without changing blood sugar levels.
Two protective proteins, alpha-Klotho and Sirtuin-1, both associated with longevity and cellular repair, increased after treatment.
An earlier pilot clinical trial in humans with diabetic kidney disease showed the same combo reduced senescent cells in skin and fat within 11 days, setting the stage for larger human trials.
You have about 37 trillion cells in your body, and a growing number of them are doing something scientists find alarming: refusing to die. These cells, which accumulate as you age, are at the center of one of the most promising new frontiers in longevity medicine, and Mayo Clinic just took a significant step forward.
Senescent cells (damaged cells that have stopped dividing but will not undergo the normal death process, known as apoptosis) build up in tissues over time and release inflammatory proteins that damage nearby healthy cells. This process, called the senescence-associated secretory phenotype or SASP, is now understood to be a key driver of aging and age-related disease, including kidney failure, arthritis, and cardiovascular decline.
The Mayo team used a two-drug senolytic regimen, meaning a treatment designed to selectively destroy senescent cells without harming healthy ones. Dasatinib is an FDA-approved cancer drug that cuts off the survival signals keeping zombie cells alive, while quercetin is a flavonoid (a natural plant compound with antioxidant properties) found in onions, apples, and green tea, and widely available as a supplement.
After just five days of combined oral treatment in a diabetic mouse model, kidney injury markers dropped, fibrosis (scarring of tissue) decreased, and inflammation fell significantly, all without any change in blood sugar levels. Two longevity-associated proteins also increased: alpha-Klotho, a hormone linked to kidney protection and slower aging, and Sirtuin-1, a protein that governs DNA repair and cellular stress response.
This matters to you because kidney function declines with age in virtually everyone, not just people with diabetes. Senescent cell accumulation is a universal feature of aging, and the idea that a short, periodic treatment could clear them and restore protective factors has implications far beyond diabetic kidney disease.
A prior human pilot trial confirmed that the combo reduced senescent cells in skin and fat tissue within 11 days, giving researchers confidence that the preclinical results will translate. Larger randomized trials in humans are now the logical next step.
Why Should You Care?
Senolytics represent one of the most direct anti-aging strategies in clinical development: instead of slowing the process, they remove the cells actively, making it worse. If the human trials confirm what the preclinical data show, a short course of a cancer drug and an over-the-counter supplement could become one of the most accessible tools in the longevity toolkit.
1. Bian X., et al. "Senolytics, dasatinib plus quercetin, reduce kidney inflammation, senescent cell abundance, and injury while restoring geroprotective factors in murine diabetic kidney disease." eBioMedicine, Feb 2026. https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(26)00005-8/fulltext
2. Mayo Clinic News Network, March 5, 2026 — https://newsnetwork.mayoclinic.org/discussion/mayo-clinic-researchers-find-combination-therapy-reduces-effects-of-zombie-cells-in-diabetic-kidney-disease/
3. PubMed abstract — https://pubmed.ncbi.nlm.nih.gov/41564845/
4. Hickson LJ., et al. "Senolytics decrease senescent cells in humans." eBioMedicine, 2019. https://pubmed.ncbi.nlm.nih.gov/31542391/
